TY - JOUR AU - Ferrando, Marcos AU - Coroleu, Buenaventura AU - Rodríguez-Tabernero, Luis AU - Barrenetxea, Gorka AU - Guix, Cristina AU - Sánchez, Fernando AU - Jenkins, Julian AU - Sanahuja, Jordi Aragonès AU - Ballesteros, Ramón Aurell AU - Quintana, Delia Báez AU - Boluda, Agustín Ballesteros AU - Ziarrusta, Gorka Barrenetxea AU - Álvarez, Emilio Bayón AU - Lletget, Buenaventura Coloreu AU - Martín, Pilar Conte AU - Arroyo, José Antonio Domínguez AU - Serrano, Marcos Ferrando AU - Iriarte, Josu Franco AU - España, José Félix García AU - Jiménez, Miguel Ángel García AU - Iñarra, María José AU - Cortés, Javier Martínez AU - Pacheco, Moisés Moreira AU - Galcerán, Cristina Guix AU - Huertos, Ángel Rocas AU - Rodríguez-Aranda, Amelia AU - Tabernero, Luis Rodríguez AU - Guadix, Bárbara Romero AU - del Carmen Sanabria Rodríguez, Mª. AU - Martín, Fernando Sánchez AU - Afonso, Alejandra Torres AU - Vives, Margarita Torres AU - Jurio, Jesús Zabaleta AU - on behalf of the BIRTH study group PY - 2020 DA - 2020/07/29 TI - The continuum of ovarian response leading to BIRTH, a real world study of ART in Spain JO - Fertility Research and Practice SP - 13 VL - 6 IS - 1 AB - The first biosimilar of recombinant follicle stimulating hormone (rFSH) launched in Europe was Bemfola® in 2014 following a clinical development programme demonstrating efficacy and safety to the satisfaction of the European Medicines Agency. Since then the increasing use of biosimilar rFSH has provided the opportunity to study both effectiveness across the whole population and the variation of rFSH use during routine clinical care in a real-world setting in Spain. SN - 2054-7099 UR - https://doi.org/10.1186/s40738-020-00081-4 DO - 10.1186/s40738-020-00081-4 ID - Ferrando2020 ER -